Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks-MedSci.cn

Biosimilar BI 695501 demonstrates clinical equivalence to adalimumab reference product in patients with moderate to severe chronic plaque psoriasis through 24 weeks

Menter, A; Arenberger, P; Balser, S; Beissert, S

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020; 83 (6): AB5

科室
- - 订阅+
  - 更多科室
工具
服务